陰道雷射用於生殖泌尿症狀之初步經驗
胡如娟1、余明螢2、王賢祥1, 3、陳卷書1, 3、李建儀1, 3, 4、張瓈文1、裘坤元1, 5
1臺中榮民總醫院外科部泌尿科; 2艾芙蘿診所; 中山醫學大學醫學研究所; 4弘光科技大學護理系; 5暨南大學應用化學系
Fractional CO2 Vaginal Laser for Genitourinary symptoms: Preliminary Experience at Taichung Veterans General Hospital
Ju-Chuan Hu1, Ming-Ying Yu2, Shian-Shiang Wang1,3, Chuan-Su Chen1,3, Jian-Ri Li1,3,4, Li-Wen Chang1, Kun-Yuan Chiu1,5
1Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung; 2Aphrodite Beauty Clinic, Taichung; 3Institute of Medicine, Chung Shan Medical University, Taichung; 4Department of Medicine and Nursing, Hung Kuang University, Taichung; 5Department of Applied Chemistry, National Chi Nan University, Naitou
Purpose:
The vaginal laser is an emerging therapy in genitourinary syndrome of menopause (GSM) by remodeling and repair of vulvovaginal atrophy. However, there was scant evidence on the applications on female Taiwanese in the literature. This study aimed to evaluate the efficacy of the genitourinary symptoms in post-partum and post-menopause women.
Materials and Methods:
This study was based on a retrospective chart review of 11 consecutive patients who underwent three times of CO2vaginal Laser (MonaLisa TouchTM; Deka, Italy) since April 2017 in our institute. Data was collected and analyzed, including age, body mass index, parity, genitourinary symptoms, along with the outcomes.
Results:
Six of eleven (54.5%) patients were post-menopause females. 72.7% (8 of 11) patients complained of mild or moderate stress urinary incontinence, and all reported satisfied improvements. All patients stated with different degrees of vaginal dryness and dyspareunia. After three times of laser therapy, the patients reported good responses on dyspareunia (88% in post-partum group v.s. 89.17% in post-menopause group, p=0.91).These improvements were most significant after first therapy while the therapeutic effects could be maintained at least nine months later.
Conclusions:
The vaginal laser could be used in female Taiwanese with GSM as previous studies in other races. It also achieved significant improvements in dyspareunia and post-partum stress urinary incontinence. However, the placebo effect is unable to excluded due to no comparison group.